This is a comparative study of HIV co-receptor usage in the early stages of HIV infection between two distinct patient groups, one with a low CD4 count (group 1), and the other with a high CD4 count (group 2). Group 1 progressed to a CD4 count below 200 cells/μL within 2 y, while group 2 had a CD4 count above 500 cells/μL within 2 y. Viral RNA was extracted from the plasma of these patients, and the C2-V5 region of the HIV-1 env genes were cloned and sequenced. The co-receptor usage was predicated based on V3 loop amino acid sequences using Geno2pheno and PSSM programs. Our results indicate that in acute HIV infection of rapid progressors (low CD4 count; group 1), the primary co-receptor usage is CXCR4, while in the high CD4 count group (group 2), the co-receptor usage is predominantly CCR5. One-year follow-up data from these patients showed no obvious change in HIV co-receptor usage in either group. Sequence analysis of patients from both study groups showed prevalence of the AE subtype, and therefore we can speculate that the CXCR4 co-receptor may be the primary HIV-1 co-receptor used in the HIV-1 AE subtype, and may be responsible for rapid HIV-1 disease progression in the MSM cohort.
Get full access to this article
View all access options for this article.
References
1.
BriggsDR, TuttleDL, SleasmanJW, GoodenowMM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages)AIDS, 2000; 14:2937–2939.
2.
CassebJ, MontanheiroP, KomninakisS, de BritoA, DuarteAJ. Human immunodeficiency virus type 1 Brazilian subtype B variant showed an increasing avidity of the anti-V3 antibodies over time compared to the subtype B US/European strain in São Paulo, Brazil. Mem Inst Oswaldo Cruz, 2004; 99:69–71.
3.
ChenY, ShenC, WuHet al.Biological properties of HIV-1 subtype B isolates from infected Chinese blood donors at different disease stages. Virology, 2009; 384:161–168.
4.
ChoiWT, AnJ. Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases. Exp Biol Med (Maywood), 2011; 236:637–647.
CornelissenM, Mulder-KampingaG, VeenstraGet al.Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol, 1995; 69:1810–1818.
7.
CavarelliM, ScarlattiG. Phenotype variation in human immunodeficiency virus type 1 transmission and disease progression. Dis Markers, 2009; 27:121–136.
De JongJJ, De RondeA, KeulenW, TersmetteM, GoudsmitJ. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol, 1992; 66:6777–6780.
10.
De WolfF, HogervorstE, GoudsmitJet al.Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses, 1994; 10:1387–1400.
11.
DelgadoE, Fernandez-GarciaA, VegaYet al.Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother, 2011.
12.
DelobelP, NugeyreMT, CazabatMet al.Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol, 2007; 45:1572–1580.
13.
FiebigEW, WrightDJ, RawalBDet al.Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS, 2003; 17:1871–1879.
14.
FouchierRA, GroeninkM, KootstraNA, TersmetteM, HuismanHG, MiedemaF, SchuitemakerH. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol, 1992; 66:3183–3187.
15.
FrangeP, ChaixML, RaymondSet al.Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol, 2010; 48:3487–3491.
16.
FrangeP, GalimandJ, GoujardCet al.High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996–2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother, 2009; 64:135–141.
17.
GarridoC, RouletV, ChuecaNet al.Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol, 2008; 46:887–891.
18.
GoodenowMM, CollmanRG. HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol, 2006; 80:965–972.
19.
GottliebGS, HeathL, NickleDCet al.HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis, 2008; 197:1011–1015.
20.
HoffmanNG, Seillier-MoiseiwitschF, AhnJ, WalkerJM, SwanstromR. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol, 2002; 76:3852–3864.
21.
Isaacman-BeckJ, HermannEA, YiYet al.Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol, 2009; 83:8208–8220.
22.
JensenMA, LiFS, van't WoutABet al.Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol, 2003; 77:13376–13388.
23.
JensenMA, van't WoutAB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev, 2003; 5:104–112.
24.
JiaoY, WangP, ZhangH, ZhangT, ZhangY, ZhuH, WuH. (2011). HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?Immunol Invest, 2003; 40:597–613.
25.
KeeleBF, GiorgiEE, Salazar-GonzalezJFet al.Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA, 2008; 105:7552–7557.
26.
LatheyJL, PrattRD, SpectorSA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis, 1997; 175:231–232.
27.
LoftinLM, KienzleM, YiY, CollmanRG. R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies. J Transl Med, 2011; 9,Suppl 1:S3.
28.
LongEM, MartinHLJr, KreissJKet al.Gender differences in HIV-1 diversity at time of infection. Nat Med, 2000; 6:71–75.
29.
MilichL, MargolinB, SwanstromR. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol, 1993; 67:5623–5634.
30.
PillaiS, GoodB, RichmanD, CorbeilJ. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses, 2003; 19:145–149.
31.
PovedaE, BrizV, Quinones-MateuM, SorianoV. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS, 2006; 20:1359–1367.
32.
RaymondS, DelobelP, ChaixMLet al.Genotypic prediction of HIV-1 subtype D tropism. Retrovirology, 2011; 8:56.
33.
RaymondS, DelobelP, MavignerMet al.Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS, 2008; 22:F11–F16.
34.
Recordon-PinsonP, SoulieC, FlandrePet al.Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother, 2010; 54:3335–3340.
35.
ReschW, HoffmanN, SwanstromR. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology, 2001; 288:51–62.
36.
RitolaK, PilcherCD, FiscusSAet al.Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol, 2004; 78:11208–11218.
SeclenE, GarridoC, Gonzalez MdelM, Gonzalez-LahozJ, de MendozaC, SorianoV, PovedaE. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother, 2010; 65:1486–1492.
SingT, LowAJ, BeerenwinkelNet al.Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther, 2007; 12:1097–1106.
43.
SkrabalK, LowAJ, DongW, SingT, CheungPK, MammanoF, HarriganPR. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol, 2007; 45:279–284.
44.
SucupiraMC, SanabaniS, CortesRMet al.Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One, 2012; 7:e30292.
45.
ZhangC, XuS, WeiJ, GuoH. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis, 2009; 13:e212.
46.
ZhuT, MoH, WangN, NamDS, CaoY, KoupRA, HoDD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science, 1993; 261:1179–1181.
47.
VogelT, KurthR, NorleyS. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol, 1994; 153:1895–1904.
48.
CabelloA, CabralM, VeraME, KieferR, AzoreroRM, EberleJ, GürtlerL, Von BrunnA. Analysis of the V3 loop sequences from 10 HIV type 1-infected AIDS patients from Paraguay. AIDS Res Hum Retroviruses, 1995; 11:1135–1137.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
